** Shares of drugmaker Regeneron REGN.O fall 13.28% to $525 premarket
** Company and partner Sanofi SASY.PA say their experimental drug, itepekimab, failed in one late-stage trial testing it for a lung disease commonly called "smoker's lung", but met the goal of another trial
** Sanofi's U.S.-listed shares down ~6.5% before the bell
** Itepekimab was being tested in former smokers in two studies for chronic obstructive pulmonary disease, a condition that mostly affects smokers but can also be caused by pollutants
** Both trials were testing if the drug was statistically significant in reducing moderate or severe flare-ups of the condition in former smokers
** Companies are assessing the data and will discuss next steps with regulatory authorities
** REGN shares down ~15% YTD
(Reporting by Manas Mishra in Bengaluru)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。